TheraRadar
← Back
Data updated: Mar 29, 2026

PRINSTON PHARMA INC

MetabolicGastroenterology
Pharma

PRINSTON PHARMA INC is a pharmaceutical company focused on Metabolic, Gastroenterology.

-
Since
7
Drugs
-
Trials
8
Approved (2yr)

Key Drugs

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
linagliptin
Metabolic
DPP-4 1 indications · 2021

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE 2025-11-03
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE 2025-11-03
APIXABAN 2025-02-27
BREXPIPRAZOLE 2025-02-24
APIXABAN 2025-02-14
BREXPIPRAZOLE 2025-01-13
APIXABAN 2024-12-17
BREXPIPRAZOLE 2024-11-12
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 86%
1 drugs
Gastroenterology 14%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Takeda big-pharma
Gastroenterology, Metabolic
ASTELLAS specialty
Gastroenterology, Metabolic
MALLINCKRODT specialty
Gastroenterology, Metabolic
Amgen biotech
Metabolic, Gastroenterology
EMD SERONO INC biotech
Metabolic, Gastroenterology